QuidelOrtho (NASDAQ:QDEL) Posts Earnings Results, Beats Estimates By $0.18 EPS

QuidelOrtho (NASDAQ:QDEL) issued its quarterly earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18, FiscalAI reports. The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.78%. The business’s revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.12 earnings per share. QuidelOrtho updated its FY 2026 guidance to 0.650-0.900 EPS.

Here are the key takeaways from QuidelOrtho’s conference call:

• Underlying business remained resilient: Q2 revenue grew 6% excluding China, with strength across labs, immunohematology, TRIAGE, and major regions outside China.
• Adjusted EBITDA rose 21% to $129 million, while EBITDA margin expanded 310 basis points to 20%, reflecting productivity improvements and disciplined expense management.
• China revenue declined 23% amid uncertainty over proposed IVD pricing guidelines, and management expects the resulting demand pressure to persist through the remainder of 2026.
• The company lowered 2026 guidance to revenue of $2.52 billion–$2.60 billion, adjusted EBITDA of $540 million–$560 million, and adjusted EPS of $0.65–$0.90, while withdrawing free cash flow guidance because of market and working-capital uncertainty.
• Management said the NULEXA point-of-care molecular platform remains on track for commercialization, with encouraging early customer engagement and expected momentum ahead of the 2027–2028 respiratory season.

QuidelOrtho Trading Down 24.8%

Shares of QuidelOrtho stock opened at $12.28 on Friday. The company has a 50-day moving average of $15.75 and a two-hundred day moving average of $17.55. QuidelOrtho has a 12-month low of $9.92 and a 12-month high of $35.58. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. The stock has a market cap of $837.37 million, a PE ratio of -0.80 and a beta of 0.68.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. JPMorgan Chase & Co. lifted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Jefferies Financial Group reaffirmed a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. Finally, Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, QuidelOrtho presently has an average rating of “Reduce” and a consensus target price of $13.62.

Institutional Investors Weigh In On QuidelOrtho

Institutional investors and hedge funds have recently modified their holdings of the company. Global Retirement Partners LLC raised its holdings in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after purchasing an additional 886 shares during the last quarter. Larson Financial Group LLC grew its holdings in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of QuidelOrtho by 250.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock valued at $93,000 after buying an additional 2,309 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of QuidelOrtho by 298.1% in the second quarter. Osaic Holdings Inc. now owns 3,300 shares of the company’s stock valued at $95,000 after buying an additional 2,471 shares in the last quarter. Finally, State of Wyoming raised its stake in shares of QuidelOrtho by 230.5% during the 2nd quarter. State of Wyoming now owns 4,524 shares of the company’s stock worth $130,000 after buying an additional 3,155 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

Key Headlines Impacting QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported second-quarter adjusted earnings of $0.13 per share, compared with analysts’ expected loss of approximately $0.05 per share and $0.12 per share a year earlier. Revenue of $630.9 million also exceeded the roughly $618.7 million consensus estimate. QuidelOrtho Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue increased approximately 3% year over year, driven primarily by growth in the Labs and Point-of-Care businesses. Excluding China, revenue growth was stronger at 6%, suggesting underlying demand was healthier outside the Chinese market. QuidelOrtho Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings-call discussion focused on operating performance across its diagnostics portfolio and the updated outlook for the remainder of 2026. Investors are likely to scrutinize whether Labs and Point-of-Care growth can offset weaker conditions in China and support a sustained recovery. QuidelOrtho Q2 2026 Earnings Call Transcript
• Negative Sentiment: QuidelOrtho lowered its full-year 2026 guidance to $0.65–$0.90 in EPS and $2.5–$2.6 billion in revenue. Those ranges are substantially below analyst expectations of about $1.85–$1.87 EPS and $2.7 billion in revenue, signaling weaker profitability and sales than previously anticipated. QuidelOrtho Second Quarter Results

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.